ESPERION THERAPEUTICS

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update

02 Aug 2022 06:00:02 By Nasdaq GlobeNewswire

Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management

25 Jul 2022 14:00:00 By Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2022 Financial Results August 2, 2022

12 Jul 2022 07:00:02 By Nasdaq GlobeNewswire

Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin

03 Jun 2022 11:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in the 2022 Jefferies Global Healthcare Conference

02 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors

01 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions

31 May 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference

17 May 2022 07:00:02 By Nasdaq GlobeNewswire

Esperion Reports First Quarter 2022 Financial Results and Provides Company Update

03 May 2022 06:00:01 By Nasdaq GlobeNewswire

Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology

02 May 2022 07:00:03 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

29 Apr 2022 16:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference

29 Apr 2022 09:00:00 By Nasdaq GlobeNewswire

Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors

28 Apr 2022 15:00:00 By Nasdaq GlobeNewswire

Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event

25 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion to Report First Quarter 2022 Financial Results May 3, 2022

19 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology

13 Apr 2022 07:00:02 By Nasdaq GlobeNewswire

Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo

03 Apr 2022 11:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference

29 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire